Table 1 Distribution of study participants, overall and by SARS-CoV-2 exposure history.

N

27

4

9

14

Age (years)

21–30

31–40

41–50

 > 50

N

10

6

5

6

N

0

1

2

1

N

7

1

1

0

N

3

4

2

5

Gender

Female

Male

N

14

13

N

3

1

N

4

5

N

7

7

Vaccine type

Moderna

Pfizer

N

11

16

N

3

1

N

2

7

N

6

8

Timing of blood sampling

Dose 1 (days after first dose)

Dose 2 (days after second dose)

Follow up (days after first dose)

Mean (range)

18.5 (11–23)

19.8 (8–26)

95.5 (70–124)

Mean (range)

14.3 (11–20)

19^a

81.0 (70–102)

Mean (range)

19.2 (16–23)

20.0 (8–26)

94.8 (79–124)

Mean (range)

19.3 (17–21)

19.7 (14–26)

100.1 (88–120)